阿尔法抑制剂对功能的长期影响 - - 系统性审查和元分析
Kidney & blood pressure research
|August 10, 2025
概括
阿尔法抑制剂对功能具有中性作用,与其他血压药物相比. 需要更多的研究才能充分了解它们对脏结果的长期影响.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔法阻断剂是当主要药物不足时高血压的辅助疗法.
- 有限的数据存在阿尔法阻断剂对脏的影响与他们的血压控制相比.
- 本综述涉及阿尔法阻断剂对功能中长期影响.
研究的目的:
- 系统地审查和元分析阿尔法阻断剂对功能的影响.
- 为了比较阿尔法阻断剂治疗与其他抗高血压药物的结局.
主要方法:
- 按照PRISMA指南进行系统审查和元分析.
- 在 Medline, Web of Science 和 ScienceDirect 搜索了英语文章.
- 包括与成年人群的研究和至少12周的随访.
主要成果:
- 包括17项涉及26,170名患者的研究;许多有局限性.
- 贝叶斯元分析表明对估计的淋巴细胞过率 (eGFR) 和血清肌素有中性的影响.
- 观察到一个小的,临床上没有意义的肌素清除量的增加.
结论:
- 关于阿尔法阻断剂对脏的长期影响,存在显著的证据缺乏.
- 目前的证据表明,与其他抗高血压药物相比,对功能具有中性或非劣势的影响.
- 需要进一步的研究来澄清阿尔法阻断剂在功能维护中的作用.
更多相关视频
05:34A Mouse Model to Evaluate the Long-Term Structural and Functional Outcomes after the Reversal of Prolonged Unilateral Ureteric Obstruction
Published on: July 18, 2025
145
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
325
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
967
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
967
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508
Antihypertensive Drugs: Direct Renin Inhibitors
823
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
823
Antihypertensive Drugs: Action of β1 Blockers
609
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
609
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
977
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
977
